RBC Capital Markets advice for Teva Pharmaceuticals
| Date | Bank | Stock | Advice | Price | Difference |
|---|---|---|---|---|---|
| January 09, 2017 | RBC Capital Markets | Teva Pharmaceuticals | Buy | 42.00 USD | 78.74 % |
Advice details
Toronto - Op 09 Jan 2017 herhalen de analisten van RBC Capital Markets hun koopadvies voor the American pharmaceutical company Teva Pharmaceuticals (ISIN: US8816242098 / Mnemo: TEVA). Het 12-maands koersdoel wordt neerwaarts bijgesteld van 68.0 USD naar 42.0 USD.
Back
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
©2025 ValueSpectrum. All Rights Reserved
Developed and maintained by 